RxDoctor Payments Data

Sanjiv Agarwala

Bethlehem, PANPI 1275505612

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Merck accounts for 88.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $34,270 and has fallen 98.9% since, to $394 in 2022.

$35,164in general payments, 2019–2025

Across 33 payments — averaging $1065.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$31K
  • Bristol Myers Squibb$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Coherus Oncology, Inc.$147
  • Takeda Pharmaceuticals U.S.A., Inc.$119
  • Sanofi$68
  • plus $59 from 2 others
$506,683in research payments, 2019–2025

Across 210 payments — averaging $2412.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$355K
  • Incyte Corporation$40K
  • Tesaro, Inc.$34K
  • E.r. Squibb & Sons, L.L.C.$33K
  • Regeneron$25K
  • Genentech, Inc.$18K
  • plus $2K from 2 others

What the payments were for

  • Consulting fees$1,7855%
  • Speaking & faculty fees$18,50053%
  • Travel & lodging$13,74639%
  • Food & beverage$1,1333%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →